The 13D confirms ASP Isotopes' intent to consummate the merger and exercise pre-funded warrants to vote at the special meeting. The key catalyst is the shareholder vote on the merger; approval is highly likely given ASP Isotopes' ~15.1% current stake and the board's support. Monitor the special meeting date and any opposition from other shareholders.
Price Chart
Executive Summary
ASP Isotopes Inc. and its wholly owned subsidiary LHE LNG Holdings LLC filed a Schedule 13D disclosing beneficial ownership of 15.1% of ENDRA Life Sciences Inc.'s common stock. The filing details a May 2026 securities purchase agreement for ~$3.8 million and a June 2026 merger agreement under which ASP Isotopes will receive 58,554,185 shares of Class B Common Stock in the combined company, expected to represent ~98.9% of voting power. The activist is effectively the merger counterparty, and the 13D formalizes its position ahead of the shareholder vote on the proposed merger.
Key Financial Metrics
Key Facts
- ASP Isotopes Inc. and LHE LNG Holdings LLC filed a Schedule 13D on October 8, 2026, disclosing beneficial ownership of 254,015 shares of ENDRA common stock (15.1% of 1,499,912 shares outstanding as of October 6, 2026).
- The stake includes 66,846 shares held directly by LHE LNG and 187,169 shares issuable upon exercise of pre-funded warrants exercisable within 60 days.
- On May 27, 2026, ENDRA entered a securities purchase agreement with LHE LNG for ~$3.8 million, including 66,846 shares, pre-funded warrants for up to 511,541 shares, and common warrants for up to 1,156,774 shares at $6.57 per share.
- On June 25, 2026, ENDRA entered a merger agreement with ASP Isotopes and affiliates; post-merger, ASP Isotopes will receive 58,554,185 shares of Class B Common Stock (10 votes per share), representing ~98.9% of combined voting power.
- The combined company will be renamed '4K Resources Inc.' with a board of seven members: five designated by Noble Africa (ASP Isotopes affiliate), one by ENDRA, and the CEO (Paul Mann, current ASP Isotopes CEO).
- ENDRA's board initiated a strategic alternatives review on March 25, 2026, and the merger agreement is the outcome of that process.
Financial Impact
ASP Isotopes invested ~$3.8 million for its current stake and will receive 58.6 million Class B shares in the combined company, representing ~98.9% voting control. The merger effectively transfers control of ENDRA to ASP Isotopes.
Risk Factors
- Shareholder vote on merger may fail if sufficient minority shareholders oppose the deal, though ASP Isotopes' 15.1% stake and board support make this unlikely.
- Post-merger, existing ENDRA shareholders will be massively diluted, with ASP Isotopes holding ~98.9% voting power and the combined company pivoting to critical materials production.
- ENDRA's cash runway is limited; the 10-K noted a March 2026 cost reduction and delayed FDA submission for its TAEUS liver application.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D Filing (Primary) | 0001477932-26-006128 |
| Document: 0001477932-26-006128-index-headers.html | 0001477932-26-006128 |
| Document: 0001477932-26-006128-index.html | 0001477932-26-006128 |
| Document: 0001477932-26-006128.txt | 0001477932-26-006128 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 425 | $4.82 | awaiting T+5 | — | $4.96 (+2.93%) |
Oct 8, 2026 19d ago | 3 | $5.46 $4.74 | ▼ −13.19% | ▼ −11.22% | $4.96 (−9.14%) |
Oct 8, 2026 19d ago | SC 13D | $5.46 $4.74 | ▼ −13.19% | ▼ −11.22% | $4.96 (−9.14%) |
Oct 1, 2026 26d ago | 425 | $6.06 $5.46 | ▼ −9.90% | ▼ −11.06% | $4.96 (−18.14%) |
Oct 1, 2026 26d ago | 8-K | $6.06 $5.46 | ▼ −9.90% | ▼ −11.06% | $4.96 (−18.14%) |
Sep 25, 2026 4w ago | 425 | $5.80 $6.31 | ▲ +8.79% | ▲ +7.59% | $4.96 (−14.47%) |
Sep 9, 2026 6w ago | 425 | $5.83 $5.13 | ▼ −12.01% | ▼ −11.67% | $4.96 (−14.91%) |
Aug 17, 2026 10w ago | 8-K | $4.51 $4.75 | ▲ +5.32% | ▲ +5.52% | $4.96 (+10.00%) |
Jul 17, 2026 14w ago | 425 | $4.99 $5.23 | ▲ +4.81% | ▲ +5.50% | $4.96 (−0.58%) |
Jul 9, 2026 15w ago | 8-K | $5.49 $5.27 | ▼ −4.01% | ▼ −3.88% | $4.96 (−9.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers